Kalorama Information

The world market for infectious disease tests is estimated at $14.5 billion in 2012 and with 5% CAGR will reach $18.3 billion in 2017, according to Kalorama Information's latest report “The World Market for Infectious Disease Diagnostic Tests.”

The recent softness of lab hematology markets in North America and Europe obscured an otherwise unprecedented period of global market development. There is rising demand for clinical hematology testing in China and the greater Asia-Pacific region.

The immunoassay market is large and in some areas locked up by large IVD companies, but there is plenty of opportunity for innovators and for niche players developing antibody or antigen-based tests, finds Kalorama Information’s latest report.

In vitro diagnostic test products that can provide clinical validation of their performance have a better chance obtaining reimbursement status, according to Kalorama Information in the new report "Reimbursement for IVD Tests."

The world market for infectious disease tests is estimated at $14.5 billion in 2012 and should grow at a slightly higher rate than the rest of the diagnostics market. The finding was made in "The World Market for Infectious Disease Diagnostic Tests."

Brazil's in vitro diagnostic test market economic growth exceeded 1 billion in 2012 and will grow to 1.4 billion by 2017, according to Kalorama Information. Growth in Brazil far exceeds growth in the world market for IVD.

The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year, according to an estimate from Kalorama Information.

The global market for cloud computing in healthcare is estimated to reach $3.9 billion for 2013, representing 21.1% growth over the 2012 year. Storage demands from e-prescribing will create sales opportunities for cloud providers.

It’s not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to Kalorama Information a multi-billion dollar market for biosimilars will arrive in the next five years.

The current government shutdown has unexpectedly brought food safety to the fore once again in the United States, according to Kalorama Information.